Mixed pharmacokinetic population study and diffusion model to describe ciprofloxacin lung concentrations

The pharmacokinetics of ciprofloxacin in plasma and lung tissue at steady-state (500 mg b.i.d.) were studied in 38 patients subjected to lung surgery for bronchial epithelioma. The mean characteristics of the patient population were: age = 60 years (range: 48-70), weight=70kg (47-95), height=165cm (range 160-170) and serum creatinine=85microM (range 62-168). Plasma samples, two for each patient and lung samples, one for each patient, were obtained and analyzed. Seven groups were made according to the time of sampling after ingestion of the 5th dose. A three-compartment model was used to describe ciprofloxacin kinetics in plasma and lung. The non-linear mixed effect model approach was used to estimate the mean and variance of the pharmacokinetic parameters. The mean +/- SD of the estimates (coefficient of variation of interindividual variability as a percentage) were central volume of distribution, 39.45+/-52.47l(133%); steady-state volume of distribution, 145.86+/-97.51l(60%), clearance of influx into lung tissue, 35.83+/-22.57l/h(63%), extrapolated elimination rate constant, 0.173+/-0.25/h and extrapolated elimination half-life, 4.02+/-0.89h. The mean +/- SD ciprofloxacin concentration versus time curve in plasma and lung at steady state was simulated using pharmacokinetic parameters and lung physiological parameters, another approach was studied to model the transport of ciprofloxacin into the lung tissue by diffusion. Ciprofloxacin concentration-time history was obtained both by experiments or simulations. The ciprofloxacin level in the lung tissue followed the ciprofloxacin plasma level with a lag time resulting from the time necessary for ciprofloxacin to diffuse through the lung.

[1]  J. Vergnaud,et al.  Calculation of the blood level of a drug taken orally with a diffusion controlled dosage form , 1995 .

[2]  T. Bergan Extravascular penetration of ciprofloxacin. A review. , 1990, Diagnostic microbiology and infectious disease.

[3]  J. Vergnaud,et al.  Prediction of In‐vivo Blood Level with Controlled‐release Dosage Forms. Effect of the Gastrointestinal Tract Time , 1996, The Journal of pharmacy and pharmacology.

[4]  Pedersen Ss Clinical efficacy of ciprofloxacin in lower respiratory tract infections. , 1989 .

[5]  J. Pocidalo,et al.  Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. , 1991, The Journal of antimicrobial chemotherapy.

[6]  M. Bergeron,et al.  Tissue penetration of ciprofloxacin after single and multiple doses , 1986, Antimicrobial Agents and Chemotherapy.

[7]  R. Wise Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues. , 1991, The American journal of medicine.

[8]  T. Bergan,et al.  Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. , 1987, The American journal of medicine.

[9]  B. Strandvik,et al.  Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients , 1992, Antimicrobial Agents and Chemotherapy.

[10]  H. Lode,et al.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration , 1985, Antimicrobial Agents and Chemotherapy.

[11]  F. Vallée,et al.  Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin , 1992, Antimicrobial Agents and Chemotherapy.

[12]  R. Echols,et al.  Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. , 1994, The Journal of antimicrobial chemotherapy.

[13]  R. Wise,et al.  Pharmacokinetics and tissue penetration of ciprofloxacin , 1983, Antimicrobial Agents and Chemotherapy.